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Abstract Retroviral integrase (IN) catalyzes the integration of
double-stranded viral DNA into the host cell genome. The
reaction can be divided in two steps: 3P-end processing and DNA
strand transfer. Here we studied the effect of short oligonucleo-
tides (ODNs) on human immunodeficiency virus type 1 (HIV-1)
IN. ODNs were either specific, with sequences representing the
extreme termini of the viral long terminal repeats, or non-
specific. All ODNs were found to competitively inhibit the
processing reaction with Ki values in the nM range for the best
inhibitors. Our studies on the interaction of IN with ODNs also
showed that: (i) besides the 3P-terminal GT, the interaction of IN
with the remaining nucleotides of the 21-mer specific sequence
was also important for an effective interaction of the enzyme with
the substrate; (ii) in the presence of specific ODNs the activity of
the enzyme was enhanced, a result which suggests an ODN-
induced conformational change of HIV-1 IN.
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1. Introduction
Replication of retroviruses depends on the integration of a
ds DNA copy of the retroviral genome into the host cell
nuclear genome [1^3]. Integration requires a virus-encoded
protein, integrase, and DNA sequences located in the U3
and U5 regions at the ends of the viral long terminal repeats
(reviewed in [4]). The integration reaction has been analyzed
in vivo and in vitro and it has been shown that it proceeds in
three steps [5^7]. The ¢rst step is 3P-processing: two nucleo-
tides (GT) from the 3P-ends of each strand of linear viral
DNA are removed by IN leaving at the viral 3P-ends the
conserved CA dinucleotide. A highly conserved feature of
all retroviruses is the presence of a CA dinucleotide immedi-
ately upstream of the cleavage site in the LTR. This sequence
is critical for site-speci¢c cleavage and integration. The second
step or strand transfer, is a concerted cleavage ligation reac-
tion during which IN makes staggered cuts in the target DNA
and ligates the recessed 3P-OH ends of the viral DNA to the
overhanging 5P-phosphate ends of the target DNA at the
cleavage site. The product of this reaction is a gapped inter-
mediate. The last step is 5P-end joining, in which the integra-
tion process is completed by removal of the two unpaired
nucleotides at the 5P-ends of the viral DNA and repair of
the gaps between the viral and target DNA sequences.
Since IN is essential for productive retroviral infection, the
enzyme is a potential target for antiviral chemotherapeutic
intervention. In contrast to HIV-1 protease and reverse tran-
scriptase, for which an extensive number of chemical inhibi-
tors have been described, there are few reports about selective
inhibitors of integrase. In the absence of a detailed complete
model of how integrase functions, structure-activity analysis
and molecular basis of retroviral DNA integration can pro-
vide some clues for the design of potent inhibitors against this
viral target.
Here we studied the interaction of short oligonucleotides
with HIV-1 IN. Our hypothesis was that ODNs having high
a⁄nity for the enzyme could o¡er a unique opportunity for
rational design of IN-targeting drugs. To address this ques-
tion we studied the in vitro processing reaction employing
puri¢ed recombinant HIV-1 IN. The e¡ect of short ODNs
on this reaction was analyzed to assess interactions with IN.
ODNs were either single-stranded or double-stranded, with
sequences related or not to the natural substrate.
Our results showed that ODNs were able to interact with
IN and that enzyme a⁄nity was higher for speci¢c than non-
speci¢c ODNs of the same length. All ODNs were competitive
inhibitors towards substrate and the Ki values for the best
inhibitors were in the nM range. This type of inhibitors which
binds strongly to the active site of HIV-1 IN provides another
type of potential therapeutic agent against the virus.
2. Materials and methods
All ODNs were synthesized as described in [8] and their concentra-
tion was determined according to [9]. Double-stranded DNA sub-
strate for 3P-end processing was prepared by annealing the 19-mer
ODN (5P-GTGTGGAAAATCTCTAGCA) with the 21-mer comple-
mentary strand (5P-ACTGCTAGAGATTTTCCA) by heating for
2 min at 90‡C and slow cooling. This ds DNA was labeled at the
3P-end with the exonuclease-free Klenow fragment of E. coli DNA
polymerase, [K-32P]dGTP and [K-32P]TTP [10].
HIV-1 IN was puri¢ed from the JSC 310 proteases de¢cient yeast
strain transformed with the integrase expression plasmid, pHIV1S-
F2IN [11]. Total protein was extracted as described in [12]. Integrase
was puri¢ed using the protocol described by Engelman and Craigie
[13] with some modi¢cations to improve the yield and purity of the
enzyme. All bu¡ers used in the puri¢cation procedure were as de-
scribed in [12], except that they contained 1 M ammonium sulfate
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and 7 mM CHAPS (to avoid aggregation of IN). The soluble fraction
obtained from yeast extract was applied to a 1 ml Hitrap butyl-Se-
pharose 4B column (Amersham Pharmacia Biotech) previously
washed with 5 volumes LSC bu¡er and then equilibrated with 5 vol-
umes HSC bu¡er containing 1 M ammonium sulfate. Proteins were
eluted by a step of HSC bu¡er without ammonium sulfate. Fractions
containing IN were pooled, diluted to 1/3 with bu¡er D (50 mM
HEPES pH 7.6, 0.1 mM EDTA, 1 mM dithiothreitol, 10% glycerol,
7 mM CHAPS) and charged on a 1 ml Hitrap Heparin-Sepharose
CL-4B column (Amersham Pharmacia Biotech). After washing with
5 volumes HS bu¡er, the column was equilibrated with 5 volumes
LSC bu¡er. IN was then eluted by a step (1 M NaCl), pooled and
diluted (1/4) with bu¡er D. The diluted solution was charged on a
second Hitrap Heparin-Sepharose CL-4B column and after extensive
washing, proteins were eluted with a linear gradient of 100% LSC
bu¡er to 100% HS bu¡er. Fractions containing IN were pooled, di-
luted (1/4) with bu¡er D and applied to a MonoS PC 1.6/5 column
(Amersham Pharmacia Biotech) equilibrated with bu¡er D plus 100
mM NaCl. Proteins were eluted with a linear gradient of 100% bu¡er
D (containing 100 mM NaCl) to 60% HS. CHAPS (7 mM) was added
to all fractions containing IN. The pooled fractions were stored at
380‡C.
IN activity was determined by measuring the 3P-end processing
reaction at 30‡C. The standard reaction mixture (20^100 Wl) con-
tained: 20 mM HEPES (pH 7.5), 10 mM DTT, 0.1 mM EDTA,
4 mM NaCl, 7.5 mM MnCl2, 0.05% NP 40, 1.5 nM ds [32P]substrate.
The reaction mixture was incubated for di¡erent times (2^60 min) in
the presence of 10^40 nM IN. The reaction products of IN-dependent
[32P](GT) dinucleotide removal were estimated using two methods: (a)
separation on 12% polyacrylamide gel electrophoresis in the presence
of 7 M urea, or (b) measuring the label remaining in the acid-insoluble
material by the utilization of dry Whatman 3MM ¢lters (15U15 mm)
presoaked in 5% trichloroacetic acid (TCA). Further treatment of the
¢lters was carried out as described in [14]. All measurements were
carried out in the linear ranges of time dependence and IN concen-
tration.
Initial rates were measured in kinetic experiments. The type of in-
hibition, Ki and Km values were estimated using the Lineweaver-Burk
plot 1/v (where v is the reaction velocity) versus 1/substrate. IC50
values were determined at substrate concentrations comparable to
Km values. In these conditions and as theoretically calculated,
IC50 = 2Ki [15]. Errors in the estimation of Ki and Km were within
10^30%.
3. Results and discussion
The ¢rst step of the integration process, 3P-end processing,
involves a sequence-speci¢c endonucleolytic cleavage of two
nucleotides. This reaction is commonly assayed with a ds oli-
gonucleotide derived from the HIV-1 U5 end of the LTR,
containing the following sequence:
point of cleavage
5P GTG TGG AAA ATC TCT AGC AsGT 3P
3P CAC ACC TTT TAG AGA TCG T CA 5P
We used this speci¢c 21-mer duplex DNA containing [32P]-
labeled GT nucleotides in the 3P-end as substrate of the 3P-
processing reaction catalyzed by HIV-1 IN. Sequence-speci¢c
removal from the 3P-end generated a radiolabeled dinucleotide
product. The kinetic analysis of IN was done by measuring
the label remaining in the acid-insoluble material after dinu-
cleotide cleavage. By determining the initial velocity of the
reaction at di¡erent substrate concentrations, we calculated
the Km for the speci¢c 21-mer duplex DNA substrate to be
1.5 þ 0.3 nM.
As we were interested in studying the interaction of HIV-1
IN with short ODNs, their e¡ect was measured in the proc-
essing reaction. ODNs were single- or double-stranded mole-
cules of di¡erent lengths (1 to 21 nucleotides) and either re-
lated (‘speci¢c’) or unrelated (‘non-speci¢c’) to the speci¢c
sequence of the 21-mer substrate.
We ¢rst study the e¡ect of non-speci¢c ODNs on the 3P-
processing reaction. Fig. 1 illustrates the results obtained with
oligo d(T)10. As shown in Fig. 1A (lane IN), sequence-speci¢c
removal from the 3P-end generated a radiolabeled dinucleotide
product detected following electrophoresis. In the presence of
increasing concentrations of oligo d(T)10 a dose-dependent
inhibition of the 3P-end processing reaction was obtained
(Fig. 1A, lanes 1^6). In Fig. 1B are presented the results
obtained in a parallel experiment in which the reaction prod-
ucts were analyzed by counting the remaining labeled material
in the acid-insoluble fraction. Oligo d(T)10 inhibited the proc-
essing reaction with an IC50 value of 25 WM. Similar patterns
of inhibition were obtained for all other oligo d(T)n. As the
measurements using both determinations matched very well,
we used the second method for quantitative kinetic experi-
ments.
The inhibitory e¡ect produced by non-speci¢c ODNs was
then analyzed as a function of the chain length. The results
Fig. 1. Inhibition of the IN-catalyzed 3P-processing reaction by oligo
d(T)10. IN (30 nM) was incubated for 30 min at 30‡C with the la-
beled ds 21-mer substrate as described in Section 2. A: Reaction
products were analyzed by 12% polyacrylamide gel electrophoresis
in the presence of 7 M urea. Complete reaction mixture containing
the labeled substrate incubated in the absence of integrase (lane S)
or in the presence of IN (lane IN). Lanes 1 to 6: same as lane IN,
but in the presence of 5, 15, 25, 35, 50 and 140 WM of oligo d(T)10,
respectively. Arrows indicate 21 and 2 nucleotides. B: Reaction
products were determined by measuring the TCA-precipitable radio-
activity remaining after IN-dependent processing. Results are ex-
pressed as relative activity, 100% corresponding to IN activity in
the absence of inhibitor.
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reported in Table 1 showed that IC50 values decreased with
ODN lengthening (n = 1 to 21). Kinetic studies of enzyme
inhibition were conducted to determine the mechanism by
which non-speci¢c ODNs inhibit HIV-1 IN (Fig. 2). The pat-
tern of inhibition showed that oligo d(T)10 was a competitive
inhibitor of the speci¢c 21-mer DNA substrate with a
Ki = 8.3 þ 1.3 WM. The same type of inhibition was obtained
for all other ODNs. In all experiments, substrate was used at
concentrations comparable to the Km value; in these condi-
tions and as predicted theoretically, IC50 = 2^3Ki. The Ki val-
ues obtained for the inhibition by ODNs were, as expected,
2^3 times lower than the corresponding IC50 (Table 1).
Next, we determined the e¡ect of speci¢c ODNs, containing
sequences related to the speci¢c 21-mer substrate. The addi-
tion of a GT dinucleotide to the processing reaction produced
an inhibitory e¡ect similar to that observed with non-speci¢c
ODNs (Fig. 3A). However, an unexpected result was obtained
when we tested the e¡ect of longer speci¢c single-stranded
ODNs on the 3P-processing reaction. In contrast to the inhib-
ition observed with non-speci¢c ODNs and also with the GT
dinucleotide, the addition of the AGT trinucleotide or longer
ODNs to the 3P-processing reaction led to a detectable in-
crease of the reaction rate at relatively low ODN concentra-
tions, followed by an inhibition at high concentrations (Fig.
3A). To investigate the nature of the activation process we
analyzed the behavior of HIV-1 IN when preincubated with
di¡erent ODNs. As shown in Fig. 3B, preincubation of the
enzyme with low concentration of GT-containing ODNs led
to an increase of the initial rate of the 3P-processing reaction.
It has been already reported, concerning integrase activation,
that preincubation of HIV-1 IN with Mn2 increased the
speci¢c activity of the enzyme [16]. The role of Mn2 appears
to be related to the induction of protein-protein interactions
able to stabilize complexes with DNA [17]. The enzyme acti-
vation we observed with IN was further studied by assaying
the e¡ect of preincubating HIV-1 IN with either Mn2 or
speci¢c ODNs. In both cases the enzyme activity was stimu-
lated (Fig. 3B). At initial velocities the activity of IN was
increased 2-fold in the presence of AGT, 4-fold with Mn2
and 6-fold with GCAGT. It is important to recall that non-
speci¢c ODNs such as oligo d(T)10 under these preincubation
conditions, did not activate the enzyme, but inhibited HIV-1
IN as described above.
To further evaluate the inhibitory e¡ect produced by spe-
ci¢c ODNs in the processing reaction, it was important to
eliminate the integrase activation produced by speci¢c
ODNs. We thus preincubated IN in the presence of Mn2
in order to obtain the ‘activated form’ of the enzyme, and
then the processing reaction was performed in the presence
of speci¢c ODNs. In Fig. 3C are presented the results with
AGT or CAGT, where it is shown that, when starting with an
Mn2-activated form of IN, an inhibition similar to that ob-
tained with non-speci¢c ODNs was obtained. In these condi-
tions, speci¢c ODNs were also competitive inhibitors towards
the substrate. The IC50 values for speci¢c ODNs were deter-
mined and they are summarized in Table 1. Although all
ODNs were capable of inhibiting the processing reaction, an
important inhibition was obtained at nmolar concentrations
with the speci¢c 21- and 19-mer ODNs.
Based on these results, we hypothesized that the e¡ect of
speci¢c ss ODNs on the processing reaction rate may be the
sum of two processes: an ODN-mediated activation of IN,
followed by an inhibitory e¡ect produced by the speci¢c
ODN, similarly to that produced by non-speci¢c ODNs. Dif-
ferent reasons may explain the activation e¡ect: (i) the in£u-
ence of speci¢c ligands on enzyme aggregation; (ii) a stimu-
lation of the transition between an inactive IN molecule to an
active one due to complex formation with ODNs; (iii) a
Table 1
E¡ect of oligonucleotides on the 3P-processing reaction catalyzed by IN
A. Speci¢c or related ODNs IC50(1) (WM) Ki Non-speci¢c ODNs IC50(2) (WM) Ki Ratioa
TMP 23000 ^
dGMP 45000 ^
GT 400 130 T2 1000 330 2.5
AGT 160 T3 500 3.1
CAGT 70 T4 220 3.1
GCAGT 40 13 T5 130 3.3
AGCAGT 20 T6 100 5
TAGCAGT 10 T7 80 8
CTCTAGCAGT 1.5 T10 25 8.3 16.7
GGAAAATCTCTAGCAGT 0.1 T17 5 50
GTGTGGAAAATCTCTAGCAGT 0.03 T21 3 100
TTTTGTAAAACCACGGCCAGT 0.5
T19GT 1.2
GTGTGGAAAATCTCTAGCAGrU 0.25
GTGTGGAAAATCTCTAGCAG 0.45
GTGTGGAAAATCTCTAGCA 0.09
B. Speci¢c or related duplex ODNsb IC50(1) (WM) Non-speci¢c duplex
ODNs
IC50(2) (WM) Ratioa
GTGTGGAAAATCTCTAGCAGTbbd(N)21 0.004 T21bA21 0.32 80
T19GTbbA19CA 0.11
GTGTGGAAAATCTCTAGCAGrUbbd(N)21 0.15
GTGTGGAAAATCTCTAGCAGbbd(N)21 0.17
GTGTGGAAAATCTCTAGCAbbd(N)21 0.012
IC50 corresponds to the ODN concentration giving 50% inhibition of the 3P-processing reaction.
Standard errors did not exceed 10^30%.
aRatio = IC50(2)/IC50(1).
bSequence of complementary d(N)21 : 5P-ACT GCT AGA GAT TTT CCA CAC-3P.
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change of the enzyme conformation leading to optimal catal-
ysis.
Results of kinetic analysis showed that ODNs are compet-
itive inhibitors that bind to the active site of IN catalyzing the
3P-processing reaction. As the inhibition experiments were
done at substrate concentrations comparable to the Km value
where, as predicted theoretically, IC50 = 2Ki, we used the IC50
values as an estimation of the a⁄nity of ODNs for HIV-1 IN.
From data in Table 1 it can be concluded that the a⁄nity of
HIV-1 IN for ODNs depends on length, sequence and struc-
ture of the inhibitory agent. While lengthening of the ODN
chain resulted always in higher a⁄nity to HIV-1 IN, the en-
hancement of a⁄nity was more important for speci¢c than for
non-speci¢c ODNs. As a result the ratio between IC50 values
of non-speci¢c and speci¢c ODNs of the same length, signi¢-
cantly increases with length (Table 1A). For example, the IC50
value for the speci¢c 21-mer ODN is about 100 times lower
than that for d(T)21. In addition, annealing of speci¢c ss
ODNs to their complementary strands also led to an increase
in a⁄nity. The a⁄nity of IN for T21xA21 duplex is about 10
times higher than that for d(T)21. Thus, the contribution to
the a⁄nity for IN of the two chains of complementary ODNs
is far from being simply additive. It seems most likely that one
chain of the duplex forms strong speci¢c contacts with the
enzyme, while the other form only weak contacts. This is
the case for other enzymes interacting with DNA we have
previously analyzed, such as DNA polymerases, topoisomer-
ases, repair and restriction enzymes [11,18^24].
Fig. 2. Inhibition produced by oligo d(T)10. Double-reciprocal plot
according to Lineweaver and Burk. The 3P-processing reaction was
performed as a function of substrate concentration as indicated. Oli-
go (T)10 was added at di¡erent concentrations: 0 (E), 3.8 WM (8),
8.3 WM (R) and 18.3 WM (b).
C
Fig. 3. A: E¡ect of speci¢c ODNs on the rate of the 3P-processing
reaction. Reaction mixture was incubated with IN for 30 min at
30‡C in the presence of GT (8), AGT (F), CAGT (R) and
GCAGT (b). B: In£uence of IN preincubation on the 3P-processing
activity. IN was preincubated at 30‡C in a ¢nal volume of 100 Wl,
using the following conditions: integrase alone preincubated for 30
min (E) ; in the presence of 15 mM MnCl2 for 30 min (R) ; with
250 WM AGT for 2 min (F) ; with 63 WM GCAGT for 2 min (8) ;
with 20 WM oligo (T)10 for 2 min (b). At di¡erent time intervals,
aliquots (10 Wl) of the preincubated mixture were drawn and the
processing reaction mixture was added. C: E¡ect of speci¢c ODNs
on the activity of preincubated IN. The enzyme was preincubated
with 15 mM MnCl2 for 30 min at 30‡C. Then, ODNs were added
and the processing reaction was performed as described above.
AGT (8) ; CAGT (E).
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Concerning the sequence, a higher a⁄nity was observed for
GT-containing ODNs compared to non-speci¢c ODNs of the
same length. Most interesting, a speci¢c 20-mer ss ODN lack-
ing the 3P-terminal T-nucleotide, or a 21-mer ss ODN in
which the 3P-end T has been replaced by a ribo U led to a
decrease of a⁄nity of 15- or 8-fold, respectively (Table 1A).
Also in the case of double-stranded ODNs, removal of the T
in 3P-end or replacement by rU, decreased the a⁄nity around
40 times (Table 1B). For these ds ODNs (20-mer without the
3P-end T or with a ribo U instead of T) the a⁄nity was com-
parable to that of non-speci¢c ds ODNs of the same length.
In contrast, a speci¢c 19-mer ss ODN without the GT at the
3P-end, presented higher a⁄nity than the 20-mer, with IC50
values similar to that of the speci¢c 21-mer ss ODN. The high
a⁄nity obtained with the 21- and the 19-mer was expected,
since these ODNs have sequences representing speci¢c sub-
strates for processing and strand transfer reactions, respec-
tively.
Di¡erent studies have been carried out in which viral DNA
end sequences were altered and e¡ects on processing were
monitored. Some reports have suggested that there is limited
sequence speci¢city required, with only the well conserved CA
dinucleotide being needed for processing and strand transfer
[25]. Other studies have suggested the importance of 2^7 base
pairs upstream of the conserved CA, with varying e¡ects on
the reaction [26^30]. Recently, the importance of residues at
positions 8^11 distal to the LTR which interact with the C-
terminal domain of IN has been reported [31].
All our results taken together show the important role of
the 3P-terminal GT dinucleotide in the a⁄nity for HIV-1 IN.
Our data also suggest that besides the 3P-terminal GT, and the
conserved CA, the interaction of IN with the remaining nu-
cleotides of the 21-mer speci¢c sequence is also important.
This was illustrated by the results obtained when the canon-
ical bases situated in the 5P-terminal fragment were changed
giving a 17-fold decrease of a⁄nity with respect to the speci¢c
21-mer. After removal of the 3P-terminal GT dinucleotide
there still can be formation of additional contacts between
IN and the cleaved chain of the substrate.
We have shown here that HIV-1 IN can interact with high
a⁄nity with short ODNs. Since the a⁄nity of ODNs may be
increased by introducing additional groups able to interact
with the enzyme, speci¢c ODNs o¡er a unique opportunity
for rational design of drugs targeted directly towards HIV-1
IN.
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